GlassScriptPhysician profile
Caryn G Hasselbring
NPI 1124086699
$17,394.11
in general payments reported to CMS, 2019-2025
40 companies · $2,684 in 2025
The $2,684 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,386 · 2020: $1,686 · 2021: $2,722 · 2022: $2,802 · 2023: $2,561 · 2024: $2,553 · 2025: $2,684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,798.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,595.22 | 2019-2025 | Enbrel, Evenity, Otezla |
| Janssen Biotech, INC. | $1,887.48 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $1,701.19 | 2019-2025 | |
| Ucb, INC. | $1,464.57 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,246.54 | 2019-2025 | |
| Abbvie INC. | $989.24 | 2019-2025 | |
| Glaxosmithkline, LLC. | $910.44 | 2019-2025 | Benlysta |
| Horizon Therapeutics Plc | $874.66 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $660.26 | 2019-2024 | Taltz |
| Astrazeneca Pharmaceuticals LP | $654.10 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $483.26 | 2019-2025 | Orencia |
| Genentech USA, INC. | $446.21 | 2019-2023 | Actemra |
| Genzyme Corporation | $421.66 | 2019-2025 | |
| Radius Health, INC. | $349.73 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.07 | 2019-2024 | Ofev, Cyltezo |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caryn Hasselbring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.